At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types (MK-3475A-F11)
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab (+) Berahyaluronidase alfa and Pembrolizumab for Non-Small Cell Lung Cancer and 2 related conditions. Active but no longer recruiting, targeting 147 participants across 45 sites in 10 countries.
Detailed Summary
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab pembrolizumab (+) berahyaluronidase alfa \[MK-3475A\] administered subcutaneously (SC) over pembrolizumab \[MK-3475\] administered intravenously (IV) in participants with multiple tumor types. There will be no hypothesis testing in this study.
Study Details
Timeline
Interventions
Fixed dose coformulated product of hyaluronidase/pembrolizumab adminstered via SC injection.
Administered via IV infusion